BioXcel Therapeutics (BTAI) CEO exercises 18,000 RSUs, updates share holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioXcel Therapeutics, Inc. director and CEO Vimal Mehta reported equity changes related to previously granted restricted stock units. He exercised 18,000 Restricted Stock Units into 18,000 shares of Common Stock at a stated price of $0.0000 per share, increasing his direct Common Stock holdings to 39,259 shares.
The filing also shows indirect ownership of 480,343 Common Stock shares held by BioXcel LLC and 125 shares held by his spouse. A prior grant of 18,000 RSUs on August 1, 2025 was scheduled to vest in full within 30 days of nine months from that grant date, subject to continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary
18,000 shares exercised/converted
Mixed
4 txns
Insider
Mehta Vimal
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 18,000 | $0.00 | -- |
| Exercise | Common Stock | 18,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct, null);
Common Stock — 39,259 shares (Direct, null);
Common Stock — 125 shares (Indirect, By Spouse)
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.
